IP Library Granted Patent US 8,598,159
Granted Patent B2
US 8,598,159 · App. 12/949,655 · Granted Dec 3, 2013

Therapeutic pyrazoloquinoline derivatives

Inventors: Alan P. Kaplan (San Diego, CA); Varsha Gupta (Encinitas, CA); Jan W. F. Wasley (Guilford, CT)
Assignee: Dart Neuroscience (Cayman) Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,159
App. No.
12/949,655
Granted
Dec 3, 2013
Kind
B2
Abstract

The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA A receptor and modulating GABA A , and use of the compound of formula I for the treatment of GABA A receptor associated disorders. The general structure of formula I is shown below and can exist in tautomeric forms: The invention further provides a method of modulation of one or more GABA A subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

Claims (32)

1. A method of treating an animal in need of enhancement of memory or cognition comprising administering to the animal an effective amount of a compound of formula (I):

or a tautomer thereof, or their pharmaceutically acceptable salts,

wherein

R is hydrogen, or oxide;

each R 1 is selected from the group consisting of hydrogen, hydroxy, halo, cyano, —CONR a R b , —NR a R b , hydroxy(C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

R 2 is selected from the group consisting of hydrogen, hydroxy, halo, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

each R a and R b is independently hydrogen, (C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, (C 1 -C 6 )alkylaryl, —S(O) z (C 1 -C 6 )alkyl, —S(O) z aryl, —C(O)(C 1 -C 6 )alkyl, —C(O)NR g (C 1 -C 6 )alkyl, —C(O)NR g aryl, —C(O)O(C 1 -C 6 )alkyl, arylOC(O)— or arylC(O)—, or R a together with R b form a heterocycle group optionally substituted with one or more R d ; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), S (sulfur), and NR c ;

each R c is independently hydrogen, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —C(O)O(C 1 -C 6 )alkyl, —C(O)Oaryl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, arylO(C 1 -C 6 )alkyl, —C(O)NR g (C 1 -C 6 )alkyl, —C(O)NR g aryl, —S(O) z (C 1 -C 6 )alkyl, —S(O) z aryl, —C(O)(C 1 -C 6 )alkyl, arylC(O)—, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, or (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

each R d is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, —C(O)NR e R f , —NR e R f , hydroxy(C 1 -C 6 )alkyl, aryl, aryl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

each R e and R f is independently selected from hydrogen, (C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, (C 1 -C 6 )alkylaryl, aryl(C 1 -C 6 )alkyl, —C(O)(C 1 -C 6 )alkyl, —S(O) z (C 1 -C 6 )alkyl, —S(O) z NR g (C 1 -C 6 )alkyl, —S(O) z aryl, —C(O)NR g (C 1 -C 6 )alkyl, —C(O)(C 1 -C 6 )alkyl, arylC(O)—, arylOC(O)—, or —C(O)O(C 1 -C 6 )alkyl;

R g is hydrogen, aryl, heteroaryl, heterocycle or (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro;

Ar is aryl optionally substituted with one or more M or heteroaryl optionally substituted with one or more M;

each Q is independently hydrogen, halo, oxo, hydroxy, —C(O)NR a R b , —NR a R b , (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro, (C 1 -C 6 )alkyl optionally substituted with one or more R d , hydroxy(C 1 -C 6 )alkyl optionally substituted with one or more R d , aryl optionally substituted with one or more R d , or aryl(C 1 -C 6 )alkyl optionally substituted with one or more R d ;

each M is independently hydrogen, halo, CF 3 , CF 2 H, hydroxy, cyano, nitro, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —NR a R b , aryl, heteroaryl or heterocycle;

each X is independently NL, oxygen, C(Q) 2 , or S(O) z ;

each L is independently hydrogen, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —C(O)O(C 1 -C 6 )alkyl, —C(O)Oaryl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, arylO(C 1 -C 6 )alkyl, —CONR e R f , —S(O) z (C 1 -C 6 )alkyl, —S(O) z aryl, —C(O)(C 1 -C 6 )alkyl, arylC(O)—, —C(O)NR g (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, or(C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

p is an integer selected from 0, 1, 2 and 3,

z is an integer selected from 0, 1, and 2; and

n is an integer selected from 0, 1, and 2.

2. The method of claim 1 , wherein:

each R 1 is selected from the group consisting of hydrogen, hydroxy, halo, cyano, —CONR a R b , —NR a R b , hydroxy(C 1 -C 6 )alkyl, amino(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

each R a and R b is independently hydrogen, (C 1 -C 6 )alkyl, —S(O) z (C 1 -C 6 )alkyl, —C(O)(C 1 -C 6 )alkyl, —C(O)NR g (C 1 -C 6 )alkyl, or —C(O)O(C 1 -C 6 )alkyl, or R a together with R b form a heterocycle group optionally substituted with one or more R d ; wherein the heterocycle group optionally comprise one or more groups selected from the group consistion of O (oxygen), S (sulfur), and NR c ;

each R c is independently hydrogen, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —C(O)O(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, —C(O)NR g (C 1 -C 6 )alkyl, —S(O) z (C 1 -C 6 )alkyl, —C(O)(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, or (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

each R d is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, —C(O)NR e R f , —NR e R f , hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro;

each R e and R f is independently selected from hydrogen, (C 1 -C 6 )alkyl, aryl, —C(O)(C 1 -C 6 )alkyl, —S(O) z (C 1 -C 6 )alkyl, —S(O) z NR g (C 1 -C 6 )alkyl, —C(O)NR g (C 1 -C 6 )alkyl, —C(O)(C 1 -C 6 )alkyl, or —C(O)O(C 1 -C 6 )alkyl;

R g is hydrogen, or (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro; and

each L is independently hydrogen, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —C(O)O(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, aryl, heteroaryl, heterocycle, —CONR e R f , —S(O) z (C 1 -C 6 )alkyl, —C(O)(C 1 -C 6 )alkyl, —C(O)NR g (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, or (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro.

3. The method of claim 1 wherein wherein said animal has an anxiety disorder, sleep disorder, depression, or schizophrenia.

4. The method of claim 3 wherein said animal has Parkinson's disease, or Huntington's disease.

5. The method of claim 1 , wherein said animal has head trauma.

6. The method of claim 1 wherein the animal is an aged animal.

7. The method of claim 1 wherein said animal has Alzheimer's disease.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2012
From: DART NEUROSCIENCE LLC
To: DART NEUROSCIENCE (CAYMAN) LTD.
Reel/Frame 029361/0977 →
MERGER Recorded Nov 8, 2012
From: HELICON THERAPEUTICS, INC.
To: DART NEUROSCIENCE LLC
Reel/Frame 029293/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2010
From: KAPLAN, ALAN P.; GUPTA, VARSHA; WASLEY, JAN W.F.
To: HELICON THERAPEUTICS, INC.
Reel/Frame 025311/0126 →
Continuity (3)
Division 12135036 · Jun 6, 2008
Provisional Application 60943005 · Jun 8, 2007
Related Publication 20110065693A1 · Mar 17, 2011